• Mintz, Levin, Cohn, Ferris, Glovsky and Popeo (New York) — a 480-lawyer AmLaw 100 firm with offices throughout the U.S. and the UK — has expanded its New York Health Law Practice with the addition of three attorneys. Andrew Roth, former head of McDermott, Will & Emery’s New York Health Law Practice, and David Ivill, also a former partner at McDermott, Will & Emery, have joined Mintz Levin’s Health Law Section as Members. Nili Yolin has joined as an associate.

• W. Paul Constantine has resigned from his position as senior VP, sales at Misonix (Farmingdale, New York), effective Jan. 15 to take a position with the venture capital firm of Kleiner, Perkins, Caufield & Byers. Constantine will provide transitional support as existing in-house sales and marketing groups assume his responsibilities. Misonix makes ultrasonic medical device technology for the treatment of cancer and other chronic conditions.

• Howard Robin has been named president/CEO for Nektar Therapeutics (San Carlos, California), effective Jan. 15. Robin will replace acting president/CEO Robert Chess who will remain company chairman. Robin formerly served as president/CEO of Sirna Therapeutics. Nektar makes drug delivery technologies.

• Robert Feeney has been appointed VP, sales and marketing at NeoGenomics (Fort Myers, Florida). Feeney recently served in a dual capacity as the director of marketing and the director of scientific and clinical affairs for US Labs, a division of Laboratory Corporation of America. NeoGenomics is a CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing.

• Suzanne Greenwood was named VP, sales, at OTN (South San Francisco), a physician services company and a distributor of products and services to the community physician market. Greenwood joins OTN as a member of the senior management team. Greenwood most recently was interim director of immunoscience medical science at BMS.